Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nichelle Renk

Pain Medicine Anchorage, AK Medical Doctor

NPI 1548300205 CMS profile 606413

2000 Abbott Rd Ste A2, Anchorage, AK 99507

Open in the dashboard

General payments

$5,326

187 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nichelle Renk of Anchorage, AK is reported in the CMS Open Payments database as having received $5,326 across 187 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $476 17
2024 General $397 17
2023 General $537 19
2022 General $1,042 33
2021 General $864 35
2020 General $524 25
2019 General $1,487 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nichelle Renk
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Nichelle Renk were reported at $476. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Nichelle Renk Pain Medicine median Middle half National median
2019 $1,487 $498 $126–$1,682 $163
2020 $524 $284 $80–$910 $114
2021 $864 $399 $112–$1,219 $132
2022 $1,042 $455 $137–$1,484 $149
2023 $537 $484 $128–$1,495 $160
2024 $397 $498 $131–$1,540 $164
2025 $476 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $1,683 54 payments
  2. Avanos Medical $891 17 payments
  3. AbbVie, Inc. $608 24 payments
  4. Pfizer Inc. $258 13 payments
  5. Medtronic, Inc. $258 7 payments
  6. Merz Pharmaceuticals, LLC $194 6 payments
  7. Allergan Inc. $190 11 payments
  8. Flexion Therapeutics, Inc. $156 4 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $145 8 payments
  10. Merz North America, Inc. $123 5 payments
  11. Other $822 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,234 185 payments
  2. Consulting Fee $84 1 payment
  3. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. Senza Spinal Cord Stimulation System $926 29 payments
  2. UBRELVY $603 23 payments
  3. Omnia $523 17 payments
  4. COOLIEF* COOLED RADIOFREQUENCY $406 8 payments
  5. Xeomin $282 9 payments
  6. NURTEC ODT Primary Care $248 13 payments
  7. Senza $234 8 payments
  8. NURTEC ODT Pain $222 11 payments
  9. GENERATOR $212 3 payments
  10. INTELLIS ADAPTIVESTIM $197 4 payments
  11. Other $1,556 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

187 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Alaska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record